Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Identifieur interne : 000630 ( Main/Exploration ); précédent : 000629; suivant : 000631Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Auteurs : Jacob Schachter [Israël] ; Antoni Ribas [États-Unis] ; Georgina V. Long [Australie] ; Ana Arance [Espagne] ; Jean-Jacques Grob [France] ; Laurent Mortier [France] ; Adil Daud [États-Unis] ; Matteo S. Carlino [Australie] ; Catriona Mcneil [Australie] ; Michal Lotem [Israël] ; James Larkin [Royaume-Uni] ; Paul Lorigan [Royaume-Uni] ; Bart Neyns [Belgique] ; Christian Blank [Pays-Bas] ; Teresa M. Petrella [Canada] ; Omid Hamid [États-Unis] ; Honghong Zhou [États-Unis] ; Scot Ebbinghaus [États-Unis] ; Nageatte Ibrahim [États-Unis] ; Caroline Robert [France]Source :
- Lancet (London, England) [ 1474-547X ] ; 2017.
Abstract
Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma. We present the final protocol-specified survival analysis.
DOI: 10.1016/S0140-6736(17)31601-X
PubMed: 28822576
Affiliations:
- Australie, Belgique, Canada, Espagne, France, Israël, Pays-Bas, Royaume-Uni, États-Unis
- Angleterre, Californie, Catalogne, Grand Londres, Grand Manchester, Hollande-Septentrionale, New Jersey, Nouvelle-Galles du Sud, Provence-Alpes-Côte d'Azur, Région de Bruxelles-Capitale
- Amsterdam, Barcelone, Bruxelles, Londres, Manchester, Marseille, Sydney
- Université de Sydney
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000294
- to stream PubMed, to step Curation: 000292
- to stream PubMed, to step Checkpoint: 000292
- to stream Ncbi, to step Merge: 004D10
- to stream Ncbi, to step Curation: 004D10
- to stream Ncbi, to step Checkpoint: 004D10
- to stream Main, to step Merge: 000625
- to stream Main, to step Curation: 000630
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).</title><author><name sortKey="Schachter, Jacob" sort="Schachter, Jacob" uniqKey="Schachter J" first="Jacob" last="Schachter">Jacob Schachter</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, Tel Hashomer, Israel. Electronic address: jacob.schachter@sheba.health.gov.il.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Division of Oncology, Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, Tel Hashomer</wicri:regionArea><wicri:noRegion>Tel Hashomer</wicri:noRegion></affiliation></author><author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of California, Los Angeles, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology and Translational Research, Melanoma Institute Australia, The University of Sydney, Mater Hospital and Royal North Shore Hospital, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology and Translational Research, Melanoma Institute Australia, The University of Sydney, Mater Hospital and Royal North Shore Hospital, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Arance, Ana" sort="Arance, Ana" uniqKey="Arance A" first="Ana" last="Arance">Ana Arance</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology and Skin Cancer, Aix Marseille University, Hôpital de la Timone, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology and Skin Cancer, Aix Marseille University, Hôpital de la Timone, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Mortier, Laurent" sort="Mortier, Laurent" uniqKey="Mortier L" first="Laurent" last="Mortier">Laurent Mortier</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, Université Lille, INSERM U1189, CHU Lille, F-59000, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, Université Lille, INSERM U1189, CHU Lille, F-59000</wicri:regionArea><wicri:noRegion>59000</wicri:noRegion><wicri:noRegion>59000</wicri:noRegion></affiliation></author><author><name sortKey="Daud, Adil" sort="Daud, Adil" uniqKey="Daud A" first="Adil" last="Daud">Adil Daud</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hematology/Oncology, University of California, San Francisco, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology/Oncology, University of California, San Francisco, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Carlino, Matteo S" sort="Carlino, Matteo S" uniqKey="Carlino M" first="Matteo S" last="Carlino">Matteo S. Carlino</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Mcneil, Catriona" sort="Mcneil, Catriona" uniqKey="Mcneil C" first="Catriona" last="Mcneil">Catriona Mcneil</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Chris O'Brien Lifehouse, Royal Prince Alfred Hospital, and Melanoma Institute Australia, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Chris O'Brien Lifehouse, Royal Prince Alfred Hospital, and Melanoma Institute Australia, Camperdown</wicri:regionArea><wicri:noRegion>Camperdown</wicri:noRegion></affiliation></author><author><name sortKey="Lotem, Michal" sort="Lotem, Michal" uniqKey="Lotem M" first="Michal" last="Lotem">Michal Lotem</name><affiliation wicri:level="1"><nlm:affiliation>Department of Melanoma and Cancer Immunotherapy, Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Melanoma and Cancer Immunotherapy, Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Royal Marsden Hospital, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medical Oncology, Royal Marsden Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Lorigan, Paul" sort="Lorigan, Paul" uniqKey="Lorigan P" first="Paul" last="Lorigan">Paul Lorigan</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology University of Manchester and the Christie NHS Foundation Trust, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medical Oncology University of Manchester and the Christie NHS Foundation Trust, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Neyns, Bart" sort="Neyns, Bart" uniqKey="Neyns B" first="Bart" last="Neyns">Bart Neyns</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Blank, Christian" sort="Blank, Christian" uniqKey="Blank C" first="Christian" last="Blank">Christian Blank</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Petrella, Teresa M" sort="Petrella, Teresa M" uniqKey="Petrella T" first="Teresa M" last="Petrella">Teresa M. Petrella</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Division of Medical Oncology/Hematology, Sunnybrook Health Sciences Center, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Division of Medical Oncology/Hematology, Sunnybrook Health Sciences Center, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Hamid, Omid" sort="Hamid, Omid" uniqKey="Hamid O" first="Omid" last="Hamid">Omid Hamid</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Zhou, Honghong" sort="Zhou, Honghong" uniqKey="Zhou H" first="Honghong" last="Zhou">Honghong Zhou</name><affiliation wicri:level="2"><nlm:affiliation>Department of BARDS, Merck & Co, Kenilworth, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of BARDS, Merck & Co, Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Ebbinghaus, Scot" sort="Ebbinghaus, Scot" uniqKey="Ebbinghaus S" first="Scot" last="Ebbinghaus">Scot Ebbinghaus</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Oncology, Merck & Co, Kenilworth, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Oncology, Merck & Co, Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Ibrahim, Nageatte" sort="Ibrahim, Nageatte" uniqKey="Ibrahim N" first="Nageatte" last="Ibrahim">Nageatte Ibrahim</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Oncology, Merck & Co, Kenilworth, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Oncology, Merck & Co, Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Gustave Roussy and Paris-Sud University, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Oncology, Gustave Roussy and Paris-Sud University, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28822576</idno><idno type="pmid">28822576</idno><idno type="doi">10.1016/S0140-6736(17)31601-X</idno><idno type="wicri:Area/PubMed/Corpus">000294</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000294</idno><idno type="wicri:Area/PubMed/Curation">000292</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000292</idno><idno type="wicri:Area/PubMed/Checkpoint">000292</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000292</idno><idno type="wicri:Area/Ncbi/Merge">004D10</idno><idno type="wicri:Area/Ncbi/Curation">004D10</idno><idno type="wicri:Area/Ncbi/Checkpoint">004D10</idno><idno type="wicri:Area/Main/Merge">000625</idno><idno type="wicri:Area/Main/Curation">000630</idno><idno type="wicri:Area/Main/Exploration">000630</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).</title><author><name sortKey="Schachter, Jacob" sort="Schachter, Jacob" uniqKey="Schachter J" first="Jacob" last="Schachter">Jacob Schachter</name><affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, Tel Hashomer, Israel. Electronic address: jacob.schachter@sheba.health.gov.il.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Division of Oncology, Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, Tel Hashomer</wicri:regionArea><wicri:noRegion>Tel Hashomer</wicri:noRegion></affiliation></author><author><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of California, Los Angeles, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology and Translational Research, Melanoma Institute Australia, The University of Sydney, Mater Hospital and Royal North Shore Hospital, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology and Translational Research, Melanoma Institute Australia, The University of Sydney, Mater Hospital and Royal North Shore Hospital, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Arance, Ana" sort="Arance, Ana" uniqKey="Arance A" first="Ana" last="Arance">Ana Arance</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology and Skin Cancer, Aix Marseille University, Hôpital de la Timone, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology and Skin Cancer, Aix Marseille University, Hôpital de la Timone, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Mortier, Laurent" sort="Mortier, Laurent" uniqKey="Mortier L" first="Laurent" last="Mortier">Laurent Mortier</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, Université Lille, INSERM U1189, CHU Lille, F-59000, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, Université Lille, INSERM U1189, CHU Lille, F-59000</wicri:regionArea><wicri:noRegion>59000</wicri:noRegion><wicri:noRegion>59000</wicri:noRegion></affiliation></author><author><name sortKey="Daud, Adil" sort="Daud, Adil" uniqKey="Daud A" first="Adil" last="Daud">Adil Daud</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hematology/Oncology, University of California, San Francisco, San Francisco, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology/Oncology, University of California, San Francisco, San Francisco, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Carlino, Matteo S" sort="Carlino, Matteo S" uniqKey="Carlino M" first="Matteo S" last="Carlino">Matteo S. Carlino</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medical Oncology, Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author><author><name sortKey="Mcneil, Catriona" sort="Mcneil, Catriona" uniqKey="Mcneil C" first="Catriona" last="Mcneil">Catriona Mcneil</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Chris O'Brien Lifehouse, Royal Prince Alfred Hospital, and Melanoma Institute Australia, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Chris O'Brien Lifehouse, Royal Prince Alfred Hospital, and Melanoma Institute Australia, Camperdown</wicri:regionArea><wicri:noRegion>Camperdown</wicri:noRegion></affiliation></author><author><name sortKey="Lotem, Michal" sort="Lotem, Michal" uniqKey="Lotem M" first="Michal" last="Lotem">Michal Lotem</name><affiliation wicri:level="1"><nlm:affiliation>Department of Melanoma and Cancer Immunotherapy, Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Melanoma and Cancer Immunotherapy, Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem</wicri:regionArea><wicri:noRegion>Jerusalem</wicri:noRegion></affiliation></author><author><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Royal Marsden Hospital, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medical Oncology, Royal Marsden Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Lorigan, Paul" sort="Lorigan, Paul" uniqKey="Lorigan P" first="Paul" last="Lorigan">Paul Lorigan</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology University of Manchester and the Christie NHS Foundation Trust, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medical Oncology University of Manchester and the Christie NHS Foundation Trust, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Neyns, Bart" sort="Neyns, Bart" uniqKey="Neyns B" first="Bart" last="Neyns">Bart Neyns</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Blank, Christian" sort="Blank, Christian" uniqKey="Blank C" first="Christian" last="Blank">Christian Blank</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Petrella, Teresa M" sort="Petrella, Teresa M" uniqKey="Petrella T" first="Teresa M" last="Petrella">Teresa M. Petrella</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Division of Medical Oncology/Hematology, Sunnybrook Health Sciences Center, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Division of Medical Oncology/Hematology, Sunnybrook Health Sciences Center, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Hamid, Omid" sort="Hamid, Omid" uniqKey="Hamid O" first="Omid" last="Hamid">Omid Hamid</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Zhou, Honghong" sort="Zhou, Honghong" uniqKey="Zhou H" first="Honghong" last="Zhou">Honghong Zhou</name><affiliation wicri:level="2"><nlm:affiliation>Department of BARDS, Merck & Co, Kenilworth, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of BARDS, Merck & Co, Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Ebbinghaus, Scot" sort="Ebbinghaus, Scot" uniqKey="Ebbinghaus S" first="Scot" last="Ebbinghaus">Scot Ebbinghaus</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Oncology, Merck & Co, Kenilworth, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Oncology, Merck & Co, Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Ibrahim, Nageatte" sort="Ibrahim, Nageatte" uniqKey="Ibrahim N" first="Nageatte" last="Ibrahim">Nageatte Ibrahim</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Oncology, Merck & Co, Kenilworth, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Oncology, Merck & Co, Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Gustave Roussy and Paris-Sud University, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Oncology, Gustave Roussy and Paris-Sud University, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author></analytic><series><title level="j">Lancet (London, England)</title><idno type="eISSN">1474-547X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma. We present the final protocol-specified survival analysis.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Belgique</li><li>Canada</li><li>Espagne</li><li>France</li><li>Israël</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Californie</li><li>Catalogne</li><li>Grand Londres</li><li>Grand Manchester</li><li>Hollande-Septentrionale</li><li>New Jersey</li><li>Nouvelle-Galles du Sud</li><li>Provence-Alpes-Côte d'Azur</li><li>Région de Bruxelles-Capitale</li></region><settlement><li>Amsterdam</li><li>Barcelone</li><li>Bruxelles</li><li>Londres</li><li>Manchester</li><li>Marseille</li><li>Sydney</li></settlement><orgName><li>Université de Sydney</li></orgName></list><tree><country name="Israël"><noRegion><name sortKey="Schachter, Jacob" sort="Schachter, Jacob" uniqKey="Schachter J" first="Jacob" last="Schachter">Jacob Schachter</name></noRegion><name sortKey="Lotem, Michal" sort="Lotem, Michal" uniqKey="Lotem M" first="Michal" last="Lotem">Michal Lotem</name></country><country name="États-Unis"><region name="Californie"><name sortKey="Ribas, Antoni" sort="Ribas, Antoni" uniqKey="Ribas A" first="Antoni" last="Ribas">Antoni Ribas</name></region><name sortKey="Daud, Adil" sort="Daud, Adil" uniqKey="Daud A" first="Adil" last="Daud">Adil Daud</name><name sortKey="Ebbinghaus, Scot" sort="Ebbinghaus, Scot" uniqKey="Ebbinghaus S" first="Scot" last="Ebbinghaus">Scot Ebbinghaus</name><name sortKey="Hamid, Omid" sort="Hamid, Omid" uniqKey="Hamid O" first="Omid" last="Hamid">Omid Hamid</name><name sortKey="Ibrahim, Nageatte" sort="Ibrahim, Nageatte" uniqKey="Ibrahim N" first="Nageatte" last="Ibrahim">Nageatte Ibrahim</name><name sortKey="Zhou, Honghong" sort="Zhou, Honghong" uniqKey="Zhou H" first="Honghong" last="Zhou">Honghong Zhou</name></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Long, Georgina V" sort="Long, Georgina V" uniqKey="Long G" first="Georgina V" last="Long">Georgina V. Long</name></region><name sortKey="Carlino, Matteo S" sort="Carlino, Matteo S" uniqKey="Carlino M" first="Matteo S" last="Carlino">Matteo S. Carlino</name><name sortKey="Mcneil, Catriona" sort="Mcneil, Catriona" uniqKey="Mcneil C" first="Catriona" last="Mcneil">Catriona Mcneil</name></country><country name="Espagne"><region name="Catalogne"><name sortKey="Arance, Ana" sort="Arance, Ana" uniqKey="Arance A" first="Ana" last="Arance">Ana Arance</name></region></country><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Grob, Jean Jacques" sort="Grob, Jean Jacques" uniqKey="Grob J" first="Jean-Jacques" last="Grob">Jean-Jacques Grob</name></region><name sortKey="Mortier, Laurent" sort="Mortier, Laurent" uniqKey="Mortier L" first="Laurent" last="Mortier">Laurent Mortier</name><name sortKey="Robert, Caroline" sort="Robert, Caroline" uniqKey="Robert C" first="Caroline" last="Robert">Caroline Robert</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Larkin, James" sort="Larkin, James" uniqKey="Larkin J" first="James" last="Larkin">James Larkin</name></region><name sortKey="Lorigan, Paul" sort="Lorigan, Paul" uniqKey="Lorigan P" first="Paul" last="Lorigan">Paul Lorigan</name></country><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Neyns, Bart" sort="Neyns, Bart" uniqKey="Neyns B" first="Bart" last="Neyns">Bart Neyns</name></region></country><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Blank, Christian" sort="Blank, Christian" uniqKey="Blank C" first="Christian" last="Blank">Christian Blank</name></region></country><country name="Canada"><noRegion><name sortKey="Petrella, Teresa M" sort="Petrella, Teresa M" uniqKey="Petrella T" first="Teresa M" last="Petrella">Teresa M. Petrella</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000630 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000630 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28822576
|texte= Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28822576" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |